Older Patients with Myopic Choroidal Neovascularization Have Poorer Vision, Study Reveals

A recent study has revealed that older patients with myopic choroidal neovascularization (mCNV) have poorer vision than their younger counterparts and are more likely to develop concomitant vitreoretinal interface abnormalities (VIA).

Photo: Myopic Choroidal Neovascularization | InStyleHealth


What is mCNV or Myopic Choroidal Neovascularization?

Myopic choroidal neovascularization (mCNV) is one of the most dreaded complications of high myopia – defined as an axial length greater than 26.5 mm or refractive error greater than -6 D. This is where the eye progressively lengthens from front to back and degenerates, and neovascularization develops.

It is now established that myopic CNV can occur in patients with any degree of myopia, even in the absence of characteristic degenerative retinal changes.

Researchers of this study said, “In addition, baseline best-corrected visual acuity (BCVA), external limiting membrane (ELM), CNV lesion size, and CNV lesion location were correlated with BCVA after 1 year of conbercept therapy. Baseline central macular thickness (CMT) may be a predictor of relapse in older mCNV patients during the one-year follow-up.”

There were 64 eyes from 64 newly diagnosed CNV patients with an average age of 51 years, 67.2% women were subjected in this study. There were 39 aged greater than 50 years, and the remaining 25 were younger patients.

In the older group, 21 patients had 12-month follow-up data available and were included in further research analyses. VIA was significantly more visualized in the older group, according to Fisher’s exact test. Average BCVA was higher in the older group and sub foveal choroidal thickness (SFCT) was lower.

By utilizing the stepwise multivariate regression analysis, it was found that baseline BCVA and ELM integrity were significant and independent prognostic factors of final BCVA after 12 months of follow-up.

The mCNV recurrence was detected in 7 of the 21 elderly patients (33.3%), occurring after an average of 9.4 months after the first injection. Higher baseline CMT was a significant predictor of recurrence.

For a complete view of the clinical research, you may click here.

 

Source: Sci Rep 2021;11:7337

If you have any suggestions, please let us know.

Post a Comment (0)
Previous Post Next Post